Karen Francoeur - Department of Medical Oncology, Dana-Farber Cancer Institute

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 20 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

Jennifer L. Crombie,Svitlana Tyekucheva,Zixu Wang,Alexandra Savell,Lisa Brennan,Jessica Lowney,Karen Francoeur,Josie Montegaard,Austin I. Kim,Jacob D. Soumerai,Jon E. Arnason, Allan Louie Cruz, Sigrid Berg,David C. Fisher,Jennifer R. Brown,Matthew S. Davids

Blood（2022）

引用14浏览0引用

A Phase 1b/2 Study of Duvelisib in Combination with FCR (DFCR) for Frontline Therapy for Younger CLL Patients

Matthew S. Davids,David C. Fisher,Svitlana Tyekucheva,Mikaela McDonough,John Hanna,Brandon Lee,Karen Francoeur,Josie Montegaard,Oreofe Odejide,Philippe Armand,Jon Arnason,Jennifer R. Brown

Leukemia（2020）

引用26浏览0WOSNATURE引用

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Jennifer L. Crombie,Svitlana Tyekucheva,Alexandra Savell,Karen Francoeur, Mark Choiniere,Josie Montegaard,Jacob D. Soumerai,Jon E. Arnason,David C. Fisher,Jennifer R. Brown,Matthew S. Davids

Blood（2019）

引用10浏览0引用

PF374 IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE‐ARM, MULTICENTER, PHASE 2 TRIAL

M.S. Davids,D.M. Brander,H.T. Kim,S. Tyekucheva,J. Bsat,A. Savell,J.M. Hellman, J. Bazemore,K. Francoeur,A. Alencar,L. Shune, M. Omaira,C.A. Jacobson,P. Armand, S. Ng,J. Crombie,A.S. LaCasce,J. Arnason,E.P. Hochberg,R.W. Takvorian,J.S. Abramson,D.C. Fisher, J.R. Brown

HemaSphereno. S1 (2019): 138-139

引用0浏览0引用

Safety Profile and Management of Adverse Events Associated With Duvelisib in Patients With Advanced Hematologic Malignancies

Karen Francoeur,Jeff Haney,Michael Baglio, Dan Powers,Josie Bazemore

AMERICAN JOURNAL OF HEMATOLOGY（2019）

引用0浏览0引用

INITIAL RESULTS OF A MULTICENTER PHASE 2 STUDY OF VENETOCLAX IN COMBINATION WITH DOSE‐ADJUSTED R‐EPOCH FOR PATIENTS WITH RICHTER'S SYNDROME (CRC‐043)

M.S. Davids,P.A. Thompson,K.A. Rogers,S. Tyekucheva,S. Pazienza,K. Francoeur,S.K. Renner, J. Bazemore, M. Rocchio,U. Ihuoma,C.A. Jacobson,D.C. Fisher,J.R. Brown

Hematological oncologyno. S2 (2019): 134-135

引用0浏览0引用

Ofatumumab Plus High Dose Methylprednisolone Followed By Ofatumumab Plus Alemtuzumab To Achieve Maximal Cytoreduction Prior To Allogeneic Transplantation For 17p Deleted Or Tp53 Mutated Chronic Lymphocytic Leukemia*

Matthew S Davids,Haesook T Kim,Lijian Yu, Guadalupe De Maeyer,Mikaela McDonough,Alexander R Vartanov, Rachael Langey,Stacey M Fernandes,Jeffrey M Hellman,Karen Francoeur,Jon Arnason,Eric D Jacobsen,Ann S LaCasce,David C Fisher,Jennifer R Brown

LEUKEMIA & LYMPHOMA（2019）

引用3浏览0WOS引用

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial

Matthew S Davids,Danielle M Brander,Haesook T Kim,Svitlana Tyekucheva,Jad Bsat,Alexandra Savell,Jeffrey M Hellman,Josie Bazemore,Karen Francoeur,Alvaro Alencar,Leyla Shune,Mohammad Omaira,Caron A Jacobson,Philippe Armand,Samuel Ng,Jennifer Crombie,Ann S LaCasce,Jon Arnason,Ephraim P Hochberg,Ronald W Takvorian,Jeremy S Abramson,David C Fisher,Jennifer R Brown, Blood Cancer Research Partnership of the Leukemia & Lymphoma Society

The Lancet. Haematologyno. 8 (2019): e419-e428

引用57浏览0WOS引用

Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (ifcr) As Frontline Therapy for Younger CLL Patients

Matthew S. Davids,Haesook T. Kim,Danielle Brander,Jad Bsat,Alexandra Savell,Karen Francoeur,Jeffrey Hellman,Caron Jacobson,Ephraim Hochberg,Ronald Takvorian,Jeremy Abramson,David Fisher,Jennifer Brown

Blood（2016）

引用17浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn